Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Mixed cellularity classical Hodgkin lymphoma (MCcHL)

Written2016-06Antonino Carbone, Annunziata Gloghini
Department of Pathology Centro di Riferimento Oncologico Aviano (CRO), Istituto Nazionale Tumori, IRCCS, Aviano, Italy; acarbone@cro.it (AC); Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; annunziata.gloghini@istitutotumori.mi.it (AG)

Abstract Over the past 50 years, a relevant progress has been made toward our understanding of classical Hodgkin lymphoma pathology and cell biology. Histologic classification evolved through different systems to the 2008 World Health Organization classification, upgraded in 2016.
Mixed cellularity is a subtype of classical Hodgkin lymphoma characterized by diagnostic Hodgkin-Reed Sternberg cells in a mixed inflammatory back-ground without sclerosis. Mononuclear Hodgkin cells can be present. The mixed cellular background is considered the hallmark of the Mixed cellularity classical Hodgkin lymphoma subtype. In particular, heterogeneous constituents including admixed eosinophils plasma cells, histiocytes and small lymphocytes are usually found. The composition of this background varies greatly.

Keywords Mixed cellularity subtype of Hodgkin Lymphoma; Hodgkin Lymphoma; classical Hodgkin lymphoma; microenvironment; clinics, pathology; genetics

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424
ICD-Morpho 9650/3 Classical Hodgkin lymphoma
Atlas_Id 1566
Other namesClassical Hodgkin lymphoma (HL): Mixed cellularity subtype
Mixed cellularity Hodgkin lymphoma
Mixed cellularity classical Hodgkin disease
Mixed cellularity Hodgkin disease

Clinics and Pathology

Note Most patients affected by mixed cellularity (MC) classical Hodgkin lymphoma (cHL) present with B symptoms and in intermediate stages (II and III), compared with frequent stage II presentation in nodular sclerosis (NS) cHL. Peripheral lymph nodes are commonly involved. Splenic and liver involvement are frequent, whereas bone marrow and other organs involvement are less frequent.
Disease Based on the characteristics of the Hodgkin and Reed-Sternberg (HRS) tumour cells (lacunar cells, multinucleated giant cells, pseudosarcomatous cells) and of the reactive infiltrate, four histologic subtypes of cHL have been distinguished: lymphocyte-rich cHL (LRCHL), nodular sclerosis (NS) cHL, mixed cellularity (MC) cHL, and lymphocyte depletion (LD) cHL. Most cHL can be classified as NS or MC subtypes.
MC is a subtype of cHL characterized by diagnostic HRS cells in a mixed inflammatory back-ground without sclerosis. Mononuclear Hodgkin cells can be present. The mixed cellular background is considered the hallmark of the MCcHL subtype. In particular, heterogeneous constituents including admixed eosinophils, plasma cells, histiocytes and small lymphocytes are usually found. The composition of this background varies greatly.
Phenotype / cell stem origin Cell origin
Like HRS cells of other cHL subtypes, the tumour cells of MCcHL derive from preapoptotic crippled Germinal Center (GC) B cells. They are derived from GC B cells that have acquired disadvantageous immunoglobulin variable chain gene mutations (Kuppers et al., 2012), have lost the expression of most B-cell genes and acquired expression of genes that are typical for other types of hematopoietic and lymphoid cells (Greaves and Gribben 2012; Steidl et al. 2012; Tiacci et al., 2012).
Phenotype
Phenotypically, tumour cells of MCcHL are CD30 and CD15 positive (Stein et al., 2008) and exhibit additional expression of the following markers:
- Plasma cell markers (MUM1/IRF4) usually positive.
- Molecules involved in Ag presentation (MHC class II, CD40, CD80, CD86) consistently positive.
Cellular components of the cHL microenvironment express molecules involved in cancer cell growth and survival (such as CD30L or CD40L), and in immune escape (programmed death 1 (PD-1). A fraction of infiltrating CD4+ T cells are regulatory T (Treg) cells. Treg cells and PD-1+ T cells also interact with HRS cells (Aldinucci et al., 2010; Liu et al., 2014; Carbone et al., 2015).
Epidemiology Classical Hodgkin lymphoma is a distinct neoplastic entity with heterogeneous epidemiological features. It accounts for approximately 10% of all malignant lymphomas (Stein et al., 2008).Classical HL is the most common cancer in patients under 20 years (adolescents and younger adults). The first peak of incidence can be observed in patients under 35 years of age, whereas a second incidence peak can be observed in the elderly (Hjalgrim et al, 2008; Stein et al., 2008).
MCcHL accounts for approximately 20-25% of cHL. MCcHL is more frequent in patients with HIV infection and in resource poor areas. The incidence of MCcHL is more frequent in male than in females and peaks at age 35-40 years.
Cytology The recognition of MCcHL is based on the presence of diagnostic HRS cells in a specific inflammatory background, the composition of which varies greatly and includes eosinophils, neutrophils, histiocytes and plasma cells. Binucleated and multinucleated HRS cells with bi- or multinucleation and huge nucleoli are pathognomonic for MCcHL identification.
 
Figure 1. A typical multinucleated Hodgkin Reed-Sternberg cell is seen at the center.
Pathology HRS cells reside in an inflammatory cell microenvironment. In MCcHL, like in other cHL subtypes, microenvironmental cell types include T- and B-reactive lymphocytes, eosinophils, granulocytes, histiocytes/macrophages, plasma cells, mast cells.
 
Figure 2. The CD30 immunostaining highlights the presence of Hodgkin Reed-Sternberg cells and some mononucleated Hodgkin cells
 
Figure 3. EBER and EBV-encoded LMP1 (inset) are expressed by multinucleated Reed-Sternberg cells as nuclear and cytoplasmic staining, respectively
Other features Virology
EBV is found in HRS cells preferentially in cases of MC and LD cHL, and less frequently in NS and LRCHL. Notably, EBV is found in HRS cells in nearly all cases of cHL occurring in patients infected with HIV (IARC 2012; Younes et al., 2014; Dolcetti et al., 2016).
Table 1. Heterogeneity of classical Hodgkin lymphoma according to the morphologic and virologic characteristics.

 

Hodgkin  lymphoma  subtype

EBV infection

 

HL of the general population

 

 

 

 

Nodular lymphocyte predominance

Absent

 

 

cHL, nodular sclerosis

Usually absent *

 

 

cHL, mixed cellularity

Usually present *

 

 

Rare types

 

 

 

cHL, lymphocyte rich

Variably present

 

 

cHL, lymphocyte depleted

Variably present

 

 

 

 

 

HIV-associated HL

 

 

 

 

cHL, lymphocyte depleted

Present

 

 

cHL, mixed cellularity

Present

 

 

Less frequent

 

 

 

cHL, lymphohistiocyoid

Present

 

 

cHL, nodular sclerosis

Present

 

Post-transplant (cHL type PTLD)

 

 

 

 

Similar to other cHL

Present

 

Iatrogenic (methotrexate)

 

 

 

 

cHL, mixed cellularity

Variably present (usually present)

 

 

 

 

 


Abbreviations. cHL, classical Hodgkin lymphoma; PTLD, post-transplant lymphoproliferative disorder

*Association with EBV is less frequent in ns (10-40%) than in mc cHL (approximately 75% of cases).

Treatment Like in other cHL subtypes, cure rates approaching 80% have been achieved in patients undergoing chemo-radiotherapy, qualifying cHL as a chemosensitive disease (Santoro et al., 1987, Canellos et al., 2014).
Prognosis MCcHL exhibit a better prognosis than that of NScHL.

Genetics

Recurrent genetic alterations have been identified in HRS cells of cHL (including MCcHL). These lesions affecting members of the NF-kappaB or JAK/STAT signalling pathways (Küppers and Re, 2007; Hartmann et al., 2008; Steidl et al., 2010; Küppers 2011; Küppers et al., 2012; Pasqualucci and Dalla Favera, 2014).
See also the pertinent section within the CARDS describing the general features of cHL (Küppers, 2011; Carbone and Gloghini, 2016).

Cytogenetics

Cytogenetics Morphological See the pertinent sections within the CARDS describing the general features of cHL (Küppers, 2011; Carbone and Gloghini, 2016).

Bibliography

Classical Hodgkin lymphoma
Carbone A, Gloghini A.
Atlas Genet Cytogenet Oncol Haematol. in press
 
Molecular Biology of Lymphomas.
Pasqualucci L, Dalla Favera R.
De Vita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th ed. De Vita VTJ, Lawrence TS, Rosemberg SA, (eds). Wolters Kluwer Health/Lippincott Williams & Wilkins, 2014; 1511-1525.
 
Hodgkin's lymphoma.
Younes A, Carbone A, Johnson P, Dabaja B, Ansell S, Kuruvilla L.
De Vita VTJ, Lawrrence TS, Rosemberg SA (eds). De Vita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2014.
 
A Review of Human Carcinogens. Part B: Biological Agents
IARC Monograph on the Evaluation of Carcinogenic Risk to Humans. Vol. 100. IARC, Lyon, France, 2012.
 
The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape
Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A
J Pathol 2010 Jul;221(3):248-63
PMID 20527019
 
Treatment of Hodgkin lymphoma: a 50-year perspective
Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, Devita VT
J Clin Oncol 2014 Jan 20;32(3):163-8
PMID 24441526
 
Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment
Carbone A, Gloghini A, Castagna L, Santoro A, Carlo-Stella C
J Pathol 2015 Sep;237(1):4-13
PMID 25953622
 
A lymphomagenic role for HIV beyond immune suppression? Blood
Dolcetti R, Gloghini A, Caruso A, Carbone A
2016 Mar 17;127(11):1403-9 doi: 10
PMID 26773045
 
Lymphoid neoplasia
Greaves P, Gribben JG
Laser-capturing the essence of Hodgkin lymphoma Blood
PMID 23197579
 
Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization
Hartmann S, Martin-Subero JI, Gesk S, Hüsken J, Giefing M, Nagel I, Riemke J, Chott A, Klapper W, Parrens M, Merlio JP, Küppers R, Bräuninger A, Siebert R, Hansmann ML
Haematologica 2008 Sep;93(9):1318-26
PMID 18641027
 
Infectious aetiology of Hodgkin and non-Hodgkin lymphomas: a review of the epidemiological evidence
Hjalgrim H, Engels EA
J Intern Med 2008 Dec;264(6):537-48
PMID 19017178
 
Hodgkin lymphoma
Küppers R, Engert A, Hansmann ML
J Clin Invest 2012 Oct;122(10):3439-47
PMID 23023715
 
The microenvironment in classical Hodgkin lymphoma: an actively shaped and essential tumor component
Liu Y, Sattarzadeh A, Diepstra A, Visser L, van den Berg A
Semin Cancer Biol 2014 Feb;24:15-22
PMID 23867303
 
TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma
Schmitz R, Hansmann ML, Bohle V, Martin-Subero JI, Hartmann S, Mechtersheimer G, Klapper W, Vater I, Giefing M, Gesk S, Stanelle J, Siebert R, Küppers R
J Exp Med 2009 May 11;206(5):981-9
PMID 19380639
 
Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment
Steidl C, Connors JM, Gascoyne RD
J Clin Oncol 2011 May 10;29(14):1812-26
PMID 21483001
 
Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma
Steidl C, Diepstra A, Lee T, Chan FC, Farinha P, Tan K, Telenius A, Barclay L, Shah SP, Connors JM, van den Berg A, Gascoyne RD
Blood 2012 Oct 25;120(17):3530-40
PMID 22955918
 
Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome
Steidl C, Telenius A, Shah SP, Farinha P, Barclay L, Boyle M, Connors JM, Horsman DE, Gascoyne RD
Blood 2010 Jul 22;116(3):418-27
PMID 20339089
 
Classical Hodgkin lymphoma, introduction.
Stein H, Delsol G, Pileri SA,Weiss LM, Poppema S, Jaffe ES. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele H, Vardiman JW (eds.) World Health Organization
Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Lyon: IARC Press, 2008: 326-329
 
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES
Blood 2016 May 19;127(20):2375-90
PMID 26980727
 
Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma
Tiacci E, Döring C, Brune V, van Noesel CJ, Klapper W, Mechtersheimer G, Falini B, Küppers R, Hansmann ML
Blood 2012 Nov 29;120(23):4609-20
PMID 22955914
 

Citation

This paper should be referenced as such :
Carbone A, Gloghini A
Mixed cellularity classical Hodgkin lymphoma (MCcHL);
Atlas Genet Cytogenet Oncol Haematol. in press
On line version : http://AtlasGeneticsOncology.org/Anomalies/MixedCellulClassicHodgkinID1566.html


External links

arrayMapMorph ( 9650/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
 
 
Disease databaseMixed cellularity classical Hodgkin lymphoma (MCcHL)
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Mon Sep 18 17:18:52 CEST 2017


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.